UK considers prescribing e-cigarettes to help smokers quit

Sep.02.2022
UK considers prescribing e-cigarettes to help smokers quit
UK scientists recommend prescribing e-cigarettes to help millions quit smoking; results show 42% of hardcore smokers successfully quit.

Electronic cigarette research around the world, particularly in developed countries, is causing concern for those who wish to maintain the ban on electronic cigarettes rather than lift it.


The Daily Mail has reported that British scientists have concluded that electronic cigarettes should be prescribed to help millions of people quit smoking. This could potentially make England the first country in the world to license e-cigarettes as a medical product.


According to the Daily Mail, 40% of those who attempted to quit smoking using a free electronic cigarette were successful within a month.


Professor Caitlin Notley from the University of East Anglia led a pilot project involving 668 patients who were using electronic cigarettes. She stated that, "it led to a successful quit attempt within four weeks for 42% of entrenched smokers. This is particularly important as it can help those who have attempted to quit smoking multiple times but have been unsuccessful, stay away from tobacco.


Professor Notley also stated that the program was "very popular" and acknowledged that "other forms of smoking cessation support are not suitable for everyone." Her team told the nicotine and tobacco research company that they hoped electronic cigarettes would be widely used because they offer nicotine without carbon monoxide or tar.


The daily newspaper reported that this study is extremely significant and has opened up new horizons for the global tobacco market. The NHS stated that electronic cigarettes are not without risks but are better than regular cigarettes.


Previous research has found that 27.2% of people use electronic cigarettes to quit smoking, while 18.2% attempt to use patches and gum.


Last year, regulatory bodies for pharmaceuticals and health products announced that any approved electronic cigarette products would require a prescription from a doctor. "Whether it's the Covid-19 vaccine we've rolled out or the innovative public health measures we've implemented to reduce the risk of severe illnesses, this country is still a global leader in healthcare," said Health Secretary Sajid Javid.


Opening the door to e-cigarettes licensed by the NHS (UK National Health Service) could potentially lead to a significant decrease in the national smoking rate," added Javid.


GoSmokeFree.co.uk conducted a survey of 1,200 respondents to gauge their opinions on the issue. The survey revealed that 35% of participants believed that these products should be available by prescription due to their potential to aid in smoking cessation. Meanwhile, 38% were in favor of banning these products altogether and 45% felt that local anti-smoking laws were not strict enough.


Experts from around the world, particularly those from the World Vapers Alliance (WVA) and WeVape, have praised the UK for embracing science and taking strong measures to reduce tobacco harm. This is something that New Delhi should follow.


Although the World Health Organization (WHO) continues to reject electronic cigarettes and other safer alternatives to nicotine through such measures, the UK has been leading the way in reducing tobacco harms and local smoking rates through its progressive e-cigarette policies.


This is the progress of UK research, where experts are urging London authorities to influence the position of the World Health Organization (WHO). "The UK is at the forefront of reducing harm and has provided an excellent example of effective smoking cessation through e-cigarettes for other parts of the world. Our government has chosen a proven and scientifically-supported path. Before the WHO conference in November, the UK needs to strengthen its commitment to e-cigarettes and encourage other countries to do the same," said Mark Oates, Director of WeVape.


Electronic cigarettes contain nicotine and are not risk-free, but experts from the UK and US have made it clear that regulated e-cigarettes are less harmful than smoking. E-cigarettes that have obtained medicinal licenses must undergo stricter safety checks.


Smoking remains a leading cause of premature death, although smoking rates in the UK are at an all-time low. However, there are still approximately 6.1 million smokers in England.


In 2020, electronic cigarettes were the most popular aid for smokers in the UK trying to quit. They have been shown to be highly effective in supporting those trying to quit smoking, with 27.2% of smokers using e-cigarettes compared to 18.2% using nicotine replacement therapies like patches and gum.


Among individuals attempting to quit smoking, those with the highest success rates include those who used electronic cigarettes to quit smoking, as well as those who utilized local smoking cessation services. From 2020 to 2021, up to 68% of individuals were able to successfully quit smoking.


The example of the United Kingdom needs to be studied carefully in India. For a country with a population exceeding one billion, the Ministry of Health and Family Welfare should work towards minimizing the human and economic losses by reducing the risks associated with tobacco use.


Officials in India's Ministry of Health should now realize that the ban is ineffective and lifting it is necessary, which should not be considered as a means of indulgence. In fact, India must consider humane regulations that are proportional to the risks and take protective measures to prevent abuse.


However, despite the world taking the correct steps, this has not been the case in the past three years. Sadly, India has not changed or made any concessions.


Indians bear a significant burden of tobacco use, with nearly a third of the population relying on some form of it. This has resulted in almost 1.4 million deaths, close to the total population of cities like Ranchi or Jabalpur. Furthermore, the World Health Organization (WHO) has stated that the annual massive loss of $27.5 billion is due to illnesses caused by tobacco use among people aged 35 and above.


The health department has initiated numerous laws to discourage people from smoking, but the most controversial is its irrational decision towards the e-cigarette industry.


Statement


This article is compiled from third-party information and is intended for the purposes of industry exchange and learning.


This article does not represent the opinions of 2FIRSTS, and 2FIRSTS is unable to verify the truthfulness and accuracy of the article's content. The translation of this article is only intended for exchange and research within the industry.


Due to limitations in translation skills, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government regarding any statements and positions related to domestic affairs, Hong Kong, Macau, Taiwan, and foreign affairs.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please kindly contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds Showcases Vuse Pro Flavors and VELO Nicotine Pouches at NACS Show 2026
Reynolds American, a BAT subsidiary, showcased four Vuse Pro flavored e-cigarette pods and its VELO nicotine pouch portfolio at NACS Show 2026. Booth staff confirmed to 2Firsts that the Vuse Pro flavors are sold in the U.S., although they have not received FDA marketing authorization. BAT outlined plans to expand Vuse retail distribution and reported that VELO held a 30.5% year-to-date volume share of the U.S. modern oral nicotine category through August 2026. The booth also featured the newly launched VELO MAX range and merchandising displays combining cigarettes, vaping products and oral nicotine brands.
EXPO
Oct.09
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
British American Tobacco (BAT)'s VELO brand launched the VELO WRKS nicotine pouch range in Sweden on November 2, 2026. The initial release features three Dual Can variants, each containing two separate flavours in a dual-compartment container. Each can holds 20 slim pouches with 8mg of nicotine per pouch and retails for SEK 52.99. According to VELO, the first release, Drop 1, is limited to 75,000 cans and will remain available until February 2027 or while stocks last. VELO positions WRKS as a platform for testing new product concepts and has introduced an online consumer feedback survey. EU trademark records show BAT applied to register VELO WRKS in March 2026 under Class 34, covering nicotine pouches, e-cigarettes, heated tobacco products and other tobacco-related goods.
product
Nov.03
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
Texas Extends Tobacco Tax Interpretation to a 6-Methylnicotine Product, Citing VELO Ruling
The Texas Comptroller of Public Accounts ruled in September 2026 that a combustible product made with non-tobacco plant material and 6-methylnicotine (6-MN), a synthetic nicotine analog, qualifies as a taxable tobacco product. The applicant said the product contained neither tobacco leaf nor measurable conventional nicotine. The determination applies reasoning from a May Texas Supreme Court decision involving VELO nicotine pouches, finding that the plant material and 6-MN together perform the functions of tobacco in a conventional smoking product. The ruling carries applicable tax, licensing and reporting obligations but is limited to the facts submitted by the taxpayer. It does not establish a blanket tax classification for all 6-MN products or extend the same conclusion to e-cigarettes.
Regulations
Nov.06
Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
Product | BAT Revises Japan's VELO Convenience Store Lineup, Adding ¥380 Mango Pouches as Selected SKUs Exit
British American Tobacco's Japanese subsidiary, BAT Japan, launched VELO Mango Ice Medium on November 2, 2026, with distribution expanding to selected 7-Eleven, FamilyMart, NewDays and Seicomart stores from November 3. The new oral tobacco product contains 15 pouches per can and retails for ¥380, featuring a mango and cooling flavor profile at Medium intensity. At the same time, BAT Japan raised prices on multiple existing VELO products from ¥360 to ¥380 per can and withdrew selected SKUs from convenience store distribution without discontinuing them entirely. The changes affect product assortment, pricing and retail channel allocation.
product
Nov.04
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives